Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2934 in Systemic Light Chain Amyloidosis
NCT07266116Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Dec 2025
- Primary completion
- Feb 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2934 in systemic light chain amyloidosis, sponsored by Chia Tai Tianqing. Started Dec 2025; status: recruiting.
02
Drugs
TQB2934
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT07266116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266116.